A new study on the phosphoproteomics analysis of tamoxifen-resistant breast cancer cells has been published from Dr. Akhilesh Pandey's lab in the recent issue of Molecular and Cellular Proteomics.
In this study, MCF7 breast cancer cell lines were chronically treated with tamoxifen for 6 months to acquire resistance. SILAC-based quantitative phosphoproteomic profiling of treated and untreated cells with a Orbitrap Velos mass spectrometer identified over 5,000 unique phosphopeptides, with over 2,000 peptides differentially phosphorylated between the two conditions.
Focal adhesion pathway was found to be enriched by pathway analysis. Silencing FAK2 suppressed cell proliferation and tumor formation. Further, high FAK2 expression was found to correlate with shorter metastasis-free survival in tamoxifen-treated breast cancer patients.
The authors suggest that FAK2 could serve as a potential therapeutic target for management of hormone refractory breast cancers.
No comments:
Post a Comment
Please provide your inputs